Park S, Namkoong H, Doh J, Choi J, Yang B, Park Y, et al. Negative role of inducible PD-1 on survival of activated dendritic cells. J Leukoc Biol. 2014;95:621-9 pubmed publisher

Cooper Z, Juneja V, Sage P, Frederick D, Piris A, Mitra D, et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014;2:643-54 pubmed publisher

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682-7 pubmed

Liang S, Latchman Y, Buhlmann J, Tomczak M, Horwitz B, Freeman G, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003;33:2706-16 pubmed

Duraiswamy J, Kaluza K, Freeman G, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73:3591-603 pubmed publisher

Chen L, Sham C, Chan A, Francisco L, Wu Y, Mareninov S, et al. Role of the immune modulator programmed cell death-1 during development and apoptosis of mouse retinal ganglion cells. Invest Ophthalmol Vis Sci. 2009;50:4941-8 pubmed publisher

Good-Jacobson K, Song E, Anderson S, Sharpe A, Shlomchik M. CD80 expression on B cells regulates murine T follicular helper development, germinal center B cell survival, and plasma cell generation. J Immunol. 2012;188:4217-25 pubmed publisher

Menke J, Lucas J, Zeller G, Keir M, Huang X, Tsuboi N, et al. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J Immunol. 2007;179:7466-77 pubmed